Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066155 | 0.85 | HCAR3 (0.36) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL8717631 | 0.84 | GAA (0.34) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL7066158 | 0.83 | LATS1 (0.39) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL7069716 | 0.78 | KDM4C (0.43) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL8717871 | 0.78 | GAA (0.35) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL7068588 | 0.78 | KDM4C (0.43) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL7068593 | 0.78 | KDM4C (0.43) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL8720086 | 0.77 | GAA (0.35) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL8717293 | 0.77 | GAA (0.35) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL8717375 | 0.77 | GAA (0.39) | GAAMAPTIDO1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045955-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | claimed |
| EP-0877748-A1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-18 | — | — | EP | claimed |
| WO-1997026264-A1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | claimed |
| WO-2003105896-A1 | COMBINED USE OF A MODULATOR OF CD3 AND A BETA CELL RESTING COMPOUND | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003045954-A1 | USE OF SELECTIVE POTASSIUM CHANNEL OPENERS | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002000222-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR THE TREATMENT OF CANCER | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000223-A1 | USE OF POTASSIUM CHANNEL AGONISTS FOR REDUCING FAT FOOD COMSUMPTION | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
| EP-0877748-A1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997026264-A1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | disclosed |